Charles C Wykoff, David M Brown, Kimberly Reed, Alyson J Berliner, Adam T Gerstenblith, Aurora Breazna, Prema Abraham, Jordana G Fein, Karen W Chu, W Lloyd Clark, Sergio Leal, Thomas Schmelter, Boaz Hirshberg, George D Yancopoulos, Robert Vitti
IMPORTANCE: Aflibercept, 8 mg, may have greater therapeutic benefits compared with aflibercept, 2 mg, in patients with neovascular age-related macular degeneration (nAMD), including potentially improved outcomes and decreased treatment burden. OBJECTIVE: To assess safety and efficacy of aflibercept, 8 mg, in patients with nAMD. DESIGN, SETTING, AND PARTICIPANTS: The CANDELA trial was a phase 2, randomized, single-masked, open-label, 44-week clinical trial conducted in the US...
August 3, 2023: JAMA Ophthalmology